Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update

Review Cardiac & Cardiovascular Systems

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes -Systematic review and meta-analysis of randomized placebo-controlled trials

Husam M. Salah et al.

Summary: In patients with cardiometabolic and kidney disease, SGLT2i improved cardiovascular and kidney outcomes, regardless of T2DM, HF, and/or CKD status. The most significant risk reduction was seen in hospitalization for HF and progression of kidney disease, while the effects on mortality, MI, and stroke varied.

AMERICAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial

Stefan D. Anker et al.

Summary: In patients with chronic heart failure with reduced ejection fraction, empagliflozin significantly improved cardiovascular and renal outcomes, regardless of baseline diabetes status, and across the continuum of HbA1c.

CIRCULATION (2021)

Add to Collection

Article Medicine, General & Internal